Merck snaps up preclinical Lexington biotech for up to $773M
Tilos Therapeutics, a quiet preclinical biotech developing treatments for cancer and autoimmune diseases, has become the latest startup to be acquired by pharmaceutical giant Merck& Co.
Merck (NYSE: MRK) announced Monday that it has agreed to pay upwards of $773 million in upfront and milestone payments for the purchase. A company spokesperson declined to disclose how much Merck paid upfront.
Privately held Tilos was founded in 2016 by Boehringer Ingelheim Venture Fund and Partn ers Healthcare’s…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news
More News: Autoimmune Disease | Biotechnology | Cancer | Cancer & Oncology | Health Management | Merck | Pharmaceuticals